Pharming Group jumps after positive trial results for immune disease drug

Pharming

11/12/2024 08:58

** Shares of Pharming Group  PHAR.AS  jump around 9% to
their highest since May after it reported positive results in
pediatric clinical trial of its investigational drug leniolisib
        ** The trial was evaluating leniolisib in children aged
4 to 11 years with activated phosphoinositide 3-kinase delta
syndrome (APDS), a rare primary immunodeficiency
  
    ** These results will support regulatory filings worldwide
in 2025, unlocking a part of the remaining around 25% of all
APDS patients not yet eligible for therapy, Kempen says in a
note
    ** "Once approved, we expect a bolus of these patients to
get on paid therapy early into the launch," the broker says 
    ** Jefferies adds that the data supports its peak sales
estimate of $340 million for the drug
    ** If gains hold, shares will see their best day in seven
months

 (Reporting by Hugo Lhomedet)
 ((Hugo.lhomedet@thomsonreuters.com))